Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (33) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (10) Apply Summaries of opinion filter Withdrawn applications (29) Apply Withdrawn applications filter Orphan designations (70) Apply Orphan designations filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (351) Apply Authorised filter Refused (1) Apply Refused filter Withdrawn (64) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (7) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (51) Apply PM: decision on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (12) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (14) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (7) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (3) Apply Yes filter

Referral type

Article 20 procedures (4) Apply Article 20 procedures filter Article 31 referrals (4) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (5) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (4) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (4) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Generic Remove Generic filter Additional monitoring (597) Apply Additional monitoring filter Biosimilar (93) Apply Biosimilar filter Orphan medicine (250) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

508 results

Remove all filtersRemove all filters

Categories Human Remove Human filter

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Paediatric investigation plans Remove Paediatric investigation plans filter

Medicine type Generic Remove Generic filter Accelerated assessment Remove Accelerated assessment filter Exceptional circumstances Remove Exceptional circumstances filter Conditional approval Remove Conditional approval filter

Sort by

List item

Human medicine European public assessment report (EPAR): ATryn

Antithrombin alfa, Antithrombin III Deficiency
Date of authorisation: 28/07/2006, , , Revision: 16, Withdrawn, Last updated: 02/07/2019
List item

Human medicine European public assessment report (EPAR): Ayvakyt

avapritinib, Gastrointestinal Stromal Tumors
Date of authorisation: 24/09/2020, , , , Revision: 4, Authorised, Last updated: 18/05/2022
List item

Human medicine European public assessment report (EPAR): Azacitidine Accord

azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Date of authorisation: 13/02/2020, , Revision: 5, Authorised, Last updated: 19/07/2022
List item

Human medicine European public assessment report (EPAR): Azacitidine betapharm

azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Date of authorisation: 24/03/2020, , Revision: 4, Authorised, Last updated: 10/06/2022
List item

Human medicine European public assessment report (EPAR): Azacitidine Mylan

azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Date of authorisation: 27/03/2020, , Revision: 4, Authorised, Last updated: 24/06/2022
List item

Human medicine European public assessment report (EPAR): Blenrep

belantamab mafodotin, Multiple Myeloma
Date of authorisation: 25/08/2020, , , , Revision: 4, Authorised, Last updated: 12/10/2022
List item

Human medicine European public assessment report (EPAR): Bortezomib Accord

bortezomib, Multiple Myeloma
Date of authorisation: 20/07/2015, , Revision: 13, Authorised, Last updated: 25/03/2022
List item

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi

bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019, , Revision: 5, Authorised, Last updated: 01/09/2021
List item

Human medicine European public assessment report (EPAR): Bortezomib Hospira

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 12, Authorised, Last updated: 01/03/2022
List item

Human medicine European public assessment report (EPAR): Bortezomib Sun

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 12, Authorised, Last updated: 09/09/2021
List item

Human medicine European public assessment report (EPAR): Brineura

cerliponase alfa, Neuronal Ceroid-Lipofuscinoses
Date of authorisation: 30/05/2017, , , , , Revision: 6, Authorised, Last updated: 16/08/2022
List item

Human medicine European public assessment report (EPAR): Busulfan Fresenius Kabi

busulfan, Hematopoietic Stem Cell Transplantation
Date of authorisation: 22/09/2014, , Revision: 9, Authorised, Last updated: 18/05/2021
List item

Human medicine European public assessment report (EPAR): Bylvay

Odevixibat, Cholestasis, Intrahepatic
Date of authorisation: 16/07/2021, , , , Revision: 2, Authorised, Last updated: 05/10/2022
List item

Human medicine European public assessment report (EPAR): Cabazitaxel Accord (updated)

cabazitaxel, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 28/08/2020, , Revision: 3, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Cabometyx

cabozantinib (s)-malate, Carcinoma, Renal Cell; Carcinomas, Hepatocellular
Date of authorisation: 09/09/2016, , Revision: 15, Authorised, Last updated: 05/12/2022
List item

Human medicine European public assessment report (EPAR): Capecitabine Accord

capecitabine, Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms
Date of authorisation: 20/04/2012, , Revision: 16, Authorised, Last updated: 10/12/2021
List item

Human medicine European public assessment report (EPAR): Capecitabine Medac

capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012, , Revision: 12, Authorised, Last updated: 25/04/2022
List item

Human medicine European public assessment report (EPAR): Capecitabine SUN

capecitabine, Stomach Neoplasms; Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms
Date of authorisation: 21/06/2013, , Revision: 3, Withdrawn, Last updated: 22/12/2016
List item

Human medicine European public assessment report (EPAR): Capecitabine Teva

capecitabine, Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms
Date of authorisation: 20/04/2012, , Revision: 15, Authorised, Last updated: 08/09/2021
List item

Human medicine European public assessment report (EPAR): Caprelsa (updated)

Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012, , Revision: 23, Authorised, Last updated: 01/02/2023
List item

Human medicine European public assessment report (EPAR): Carmustine Obvius

carmustine, Hodgkin Disease; Lymphoma, Non-Hodgkin
Date of authorisation: 18/07/2018, , Revision: 7, Authorised, Last updated: 20/09/2022
List item

Human medicine European public assessment report (EPAR): Carvykti (updated)

ciltacabtagene autoleucel, Multiple Myeloma
Date of authorisation: 25/05/2022, , , , Revision: 1, Authorised, Last updated: 17/01/2023
List item

Human medicine European public assessment report (EPAR): Caspofungin Accord

caspofungin acetate, Candidiasis; Aspergillosis
Date of authorisation: 11/02/2016, , Revision: 6, Withdrawn, Last updated: 20/08/2021
List item

Human medicine European public assessment report (EPAR): Celsunax

ioflupane (123i), Radionuclide Imaging; Dementia; Movement Disorders
Date of authorisation: 17/06/2021, , Authorised, Last updated: 02/07/2021
List item

Human medicine European public assessment report (EPAR): Ceplene (updated)

Histamine dihydrochloride, Leukemia, Myeloid, Acute
Date of authorisation: 07/10/2008, , , Revision: 12, Authorised, Last updated: 30/01/2023